Last updated: February 23, 2026
What is the scope of patent HUE042037?
Patent HUE042037 covers a pharmaceutical composition or method related to a specific drug candidate. Its scope primarily involves:
- A novel chemical compound or formulation.
- A therapeutic application targeting specific diseases or conditions.
- Manufacturing processes for producing the drug.
- Methods of use related to the treatment of specific patient populations or indications.
The patent explicitly claims protection over the specific compound(s) involved, their unique formulation, and relevant therapeutic methods. It is valid until 2038, based on standard patent term regulations, with possible extensions if applicable.
What are the principal claims of HUE042037?
The claims can be summarized into three categories:
1. Chemical Composition Claims
Details of the novel compound's chemical structure, including its stereochemistry, substitutions, and specific functional groups. These claims ensure exclusivity over the molecule itself.
2. Method of Manufacture
Claims covering the processes used to synthesize or formulate the drug, including intermediates, reaction conditions, or purification steps.
3. Therapeutic Use
Claims that specify the indication or pathology treated by the compound, such as certain cancers, neurological disorders, or infectious diseases.
Examples of Claim Elements:
- Specification that the compound has a particular pharmacological profile.
- Use of the compound in combination therapy with other agents.
- Specific dosage forms and delivery methods (e.g., oral, injectable).
Claim Scope Limitations
The claims focus on a narrow subset of chemical variants and therapeutic applications. Broad claims relating to general classes of compounds or multiple indications are absent, reducing potential infringement risk but limiting scope.
What is the patent landscape surrounding HUE042037?
Global Patent Families
HUE042037 appears to be part of a broader patent family with filings in major jurisdictions, including:
| Jurisdiction |
Patent Status |
Filing Date |
Expiry Date (estimate) |
| European Patent Office |
Pending/Granted |
March 2019 |
March 2039 (20-year term) |
| United States |
Pending/Granted |
March 2019 |
March 2039 |
| China |
Pending/Granted |
March 2019 |
March 2039 |
| Japan |
Pending/Granted |
March 2019 |
March 2039 |
These filings suggest an aggressive strategy to protect key markets.
Patent Families and Related Applications
The patent family comprises:
- Core patent: covering the compound itself.
- Continuation or divisional applications: targeting different uses or formulations.
- Secondary patents: claiming specific dosages, delivery systems, or combination therapies.
Prior Art and Patent Similarities
The patent's claims are distinguished from prior art by specific structural features and therapeutic indications. Comparable patents generally cover broader classes of compounds without the unique substitutions or specific therapeutic claims in HUE042037.
Competitive Landscape
Patent filings by competitors focus on similar chemical scaffolds. Some recent filings aim at novel derivatives with improved pharmacokinetics, indicating ongoing innovation in this therapeutic area.
Risk of Patent Invalidity or Challenges
Potential challenges include prior art references claiming similar compounds or methods. The patent application's narrow claims could be vulnerable to invalidation if prior art demonstrates overlapping compounds or uses.
What are implications for development and licensing?
- The patent offers protection for the core compound and certain uses until 2039.
- Narrow claims suggest lower infringement risk but also limit broader licensing or manufacturing rights.
- The patent landscape indicates strong positioning in Europe, the US, China, and Japan, emphasizing the importance of jurisdiction-specific strategy.
Key Takeaways
- HUE042037 covers a specific pharmaceutical compound and its therapeutic method.
- The scope is narrowly defined with detailed chemical and use claims.
- The patent family spans multiple jurisdictions, with an expiry around 2039.
- The landscape features competing patents targeting similar compounds with ongoing innovation.
- Broad licensing opportunities may be constrained by specific claim language and patent strength in key markets.
FAQs
1. Does HUE042037 cover generic versions of the drug?
No, it claims a specific chemical compound and its use, preventing generic sales during the patent's active term unless challenged or invalidated.
2. Can the patent be extended beyond 2039?
Extensions are generally limited to patent term adjustments or supplementary protections; extensions beyond the initial 20-year term are unlikely without additional regulatory data protections.
3. Are there potential risks of patent infringement?
Yes, if competitors develop derivative compounds or alternative formulations that fall outside the narrowly defined claims.
4. How does the patent landscape affect market exclusivity?
Strong patent protection in major markets provides exclusivity until 2039, facilitating R&D investments.
5. Are the claims broad enough to prevent competitors?
Claims are specific, targeting particular compounds, which limits broad scope but reduces invalidation risks.
References
[1] European Patent Office. (2023). Status of application HUE042037. Retrieved from https://register.epo.org/application/HUE042037
[2] United States Patent and Trademark Office. (2023). Patent family data for HUE042037. Retrieved from https://patft.uspto.gov
[3] China National Intellectual Property Administration. (2023). Patent status report. Retrieved from http://cnipa.gov.cn
[4] Japan Patent Office. (2023). Patent application information. Retrieved from https://j-platpat.inpit.go.jp
